Literature DB >> 43662

The effect of sulfasalazine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis.

L Molin, O Stendahl.   

Abstract

Sulfasalazine and its active components, 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP), are potent modulators of inflammatory reactions but with somewhat different modes of action. Investigating the effect of these compounds on normal human polymorphonuclear leukocytes in vitro, we show inhibition of different stages in the phagocytic process, such as migration (sulfasalazine and SP), superoxide production (sulfasalazine and SP), myeloperoxidase-mediated iodination and cytotoxicity (5-ASA and SP). It is thus suggested that sulfasalazine is not just a vehicle for delivering its active components in the colon, but that its therapeutic effect is ulcerative colitis and other inflammatory reactions is a result of the concurrent action of the three compounds.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 43662     DOI: 10.1111/j.0954-6820.1979.tb13545.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  24 in total

Review 1.  Sulfasalazine. Multiplicity of action.

Authors:  T S Gaginella; R E Walsh
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

Review 2.  Inflammatory intermediaries in inflammatory bowel disease.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Int J Colorectal Dis       Date:  1989       Impact factor: 2.571

Review 3.  Sulphasalazine in ulcerative colitis: in memoriam?

Authors:  J Hayllar; I Bjarnason
Journal:  Gut       Date:  1991-05       Impact factor: 23.059

Review 4.  Phagocytes, toxic oxygen metabolites and inflammatory bowel disease: implications for treatment.

Authors:  J G Williams
Journal:  Ann R Coll Surg Engl       Date:  1990-07       Impact factor: 1.891

5.  Scavenging of reactive oxygen and nitrogen species by the prodrug sulfasalazine and its metabolites 5-aminosalicylic acid and sulfapyridine.

Authors:  Diana Couto; Daniela Ribeiro; Marisa Freitas; Ana Gomes; José L F C Lima; Eduarda Fernandes
Journal:  Redox Rep       Date:  2010       Impact factor: 4.412

Review 6.  Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy.

Authors:  A B Hawthorne; C J Hawkey
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

7.  5-Aminosalicylic acid concentration in mucosal interstitium of cat small and large intestine.

Authors:  M B Grisham; D N Granger
Journal:  Dig Dis Sci       Date:  1989-04       Impact factor: 3.199

8.  Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine.

Authors:  H Allgayer; J Eisenburg; G Paumgartner
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Modulation of human colonic arachidonic acid metabolism by sulfasalazine.

Authors:  C J Hawkey; N K Boughton-Smith; B J Whittle
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

10.  Inhibition of leucocyte motility by drugs used in ulcerative colitis.

Authors:  J M Rhodes; T C Bartholomew; D P Jewell
Journal:  Gut       Date:  1981-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.